Natalie Schub
Overview
Explore the profile of Natalie Schub including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
91
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Spath N, Nakov P, Schuster S, Kownatzki-Danger D, Steppat D, Oschlies I, et al.
Transplantation
. 2025 Feb;
108(12):e430-e432.
PMID: 40020173
No abstract available.
2.
Whole-Exome Sequencing, Mutational Signature Analysis, and Outcome in Multiple Myeloma-A Pilot Study
Oelschlager L, Kunstner A, Frey F, Leitner T, Leypoldt L, Reimer N, et al.
Int J Mol Sci
. 2025 Jan;
25(24.
PMID: 39769182
The complex and heterogeneous genomic landscape of multiple myeloma (MM) and many of its clinical and prognostic implications remains to be understood. In other cancers, such as breast cancer, using...
3.
Schroeder T, Martens T, Fransecky L, Valerius T, Schub N, Pott C, et al.
Intensive Care Med
. 2024 Aug;
50(9):1459-1469.
PMID: 39172238
The use of chimeric antigen receptor T (CAR-T) cells is a significant therapeutic improvement increasing the prognosis for patients with a variety of hematological malignancies. However, this therapy has also...
4.
Gallin V, Nolle B, Schub N, Roider J
Cornea
. 2024 Jun;
44(2):196-202.
PMID: 38900711
Purpose: The treatment of patients with relapsed/refractory multiple myeloma (RRMM) with the antibody-drug conjugate belantamab mafodotin is affected by ocular adverse effects, most frequently keratopathy with corneal microcyst-like epithelial changes...
5.
Gagelmann N, Dima D, Merz M, Hashmi H, Ahmed N, Tovar N, et al.
J Clin Oncol
. 2024 Feb;
42(14):1665-1675.
PMID: 38358946
Purpose: Although chimeric antigen receptor T therapy (CAR-T) cells are an established therapy for relapsed/refractory multiple myeloma (RRMM), there are no established models predicting outcome to identify patients who may...
6.
Philippen L, Schub N, Gunther A, Cario G, Schrappe M, Repp R, et al.
Bone Marrow Transplant
. 2023 Nov;
59(1):153-155.
PMID: 37932418
No abstract available.
7.
Tilmont R, Yakoub-Agha I, Eikema D, Zinger N, Haenel M, Schaap N, et al.
Bone Marrow Transplant
. 2023 Aug;
58(11):1182-1188.
PMID: 37543712
In the setting of a first relapse of multiple myeloma (MM), a second autologous stem cell transplant (ASCT) following carfilzomib-lenalidomide-dexamethasone (KRd) is an option, although there is scarce data concerning...
8.
Finke J, Schmoor C, Stelljes M, Burchert A, Dreger P, Hegenbart U, et al.
Bone Marrow Transplant
. 2022 Aug;
57(11):1664-1670.
PMID: 35982219
Therapeutic options for patients with AML relapsing after allogeneic HCT range from chemotherapy or hypomethylating agents with or without donor lymphocyte infusions to a 2nd allogeneic HCT. Available data are...
9.
Nabergoj M, Mauff K, Beelen D, Ganser A, Kroger N, Stolzel F, et al.
Bone Marrow Transplant
. 2022 Apr;
57(7):1072-1078.
PMID: 35459878
We performed a registry study on therapy-related myeloid neoplasm (t-MN), both therapy-related myelodysplastic syndrome (t-MDS) and acute myeloid leukemia (t-AML) following treatment for breast cancer who underwent a first allogeneic...
10.
Gay F, Gunther A, Offidani M, Engelhardt M, Salvini M, Montefusco V, et al.
Cancer
. 2021 Jun;
127(18):3413-3421.
PMID: 34181755
Background: Combined therapy with carfilzomib, bendamustine, and dexamethasone was evaluated in this multicenter phase 1/2 trial conducted within the European Myeloma Network (EMN09 trial). Methods: Sixty-three patients with relapsed/refractory multiple...